Baxter International Inc. reported fourth-quarter 2025 sales from continuing operations of $2.97 billion, an 8% increase on a reported basis. However, the company's results did not meet expectations, with a U.S. GAAP diluted EPS loss of ($2.01) and an adjusted diluted EPS of $0.44, a 24% decrease from the prior year. This was primarily due to unfavorable product mix, non-recurring items, and a higher effective tax rate. The company is implementing a new operating model to simplify its organization and improve performance.

Baxter International Inc. delivered a performance in line with its guidance for the second quarter of 2025, with worldwide sales from continuing operations reaching $2.81 billion, a 4% increase on a reported basis. The company reported GAAP diluted EPS of $0.24 and adjusted diluted EPS of $0.59. A key highlight was the appointment of Andrew Hider as the new President and CEO, signaling a focus on accelerating innovation and sustainable growth.

Baxter delivered a solid Q1 2025, achieving 5% revenue growth and surpassing EPS expectations, fueled by strength across all segments, especially in Medical Products & Therapies and Healthcare Systems & Technologies.

Baxter's Q4 2024 revenue totaled $2.75 billion, up 1% year-over-year, exceeding expectations. Adjusted EPS, including discontinued operations, was $0.77, surpassing prior guidance. Strong sales in Pharmaceuticals and Medical Products & Therapies offset weaker results in Healthcare Systems & Technologies. Net income from continuing operations was negative due to special items, including goodwill impairments and restructuring costs.

Baxter reported Q3 2024 sales of $3.85 billion, with $2.70 billion from continuing operations, a 4% increase year-over-year. GAAP EPS was $0.27, and adjusted EPS was $0.80, exceeding guidance. The company is progressing in restoring production at its North Cove facility after Hurricane Helene.

Baxter International Inc. reported a 3% increase in worldwide sales from continuing operations, totaling $3.81 billion. U.S. GAAP diluted EPS from continuing operations was ($0.62), while adjusted diluted EPS from continuing operations reached $0.68, both exceeding previous guidance. The company has raised its full-year sales and adjusted diluted EPS guidance.

Baxter's first-quarter sales from continuing operations reached $3.59 billion, a 2% increase on a reported basis and a 3% increase on a constant currency basis, exceeding expectations. U.S. GAAP diluted EPS from continuing operations was $0.07, while adjusted diluted EPS from continuing operations was $0.65, also exceeding guidance.

Baxter International Inc. reported a 4% increase in worldwide sales from continuing operations, totaling $3.89 billion for the fourth quarter. U.S. GAAP diluted EPS from continuing operations was $0.14, and adjusted diluted EPS from continuing operations was $0.88. The company's performance exceeded previous guidance due to strong sales in Medical Products and Therapies, Kidney Care, and Pharmaceuticals segments.

Baxter reported a 3% increase in worldwide sales from continuing operations, totaling $3.71 billion. U.S. GAAP EPS from continuing operations was $0.09, while adjusted EPS from continuing operations reached $0.68, exceeding previous guidance. The company completed the divestiture of its BioPharma Solutions (BPS) business and is progressing with the planned spinoff of its Kidney Care segment.

Baxter reported a 3% increase in second-quarter revenues on a reported basis and a 4% increase on a constant currency basis, exceeding previously issued guidance. U.S. GAAP EPS was ($0.28), while adjusted EPS was $0.66. The company is progressing with its transformational actions, including the planned spinoff of its Renal Care and Acute Therapies businesses and the divestiture of its BioPharma Solutions business.

Baxter's first-quarter 2023 results showed a worldwide sales decrease of 2% on a reported basis, totaling $3.65 billion, but an increase of 2% on a constant currency basis. U.S. GAAP earnings per share (EPS) totaled $0.09, while adjusted EPS totaled $0.59. The company is advancing its strategic transformation initiatives, including a new operating model and the proposed spinoff of its Kidney Care segment.

Baxter International Inc. reported fourth-quarter sales of $3.9 billion, an 11% increase on a reported basis. U.S. GAAP diluted earnings per share (EPS) was $0.36, and adjusted diluted EPS was $0.88. The company is implementing a new operating model and planning a spinoff of Renal Care and Acute Therapies businesses.

Baxter's third-quarter results were impacted by significant impairment charges of $3.1 billion related to the Hillrom acquisition, reflecting rising interest rates and broad declines in equity valuations. While worldwide sales increased by 17% on a reported basis, U.S. GAAP EPS was ($5.83), with adjusted EPS totaling $0.82.

Baxter International Inc. reported a 21% increase in worldwide sales, reaching $3.75 billion for the second quarter of 2022. U.S. GAAP earnings per share (EPS) totaled $0.50, while adjusted EPS reached $0.87. The company's performance was driven by its diverse portfolio and the recent acquisition of Hillrom.

Baxter's first-quarter 2022 results showed a 26% increase in revenue to $3.7 billion, driven by the Hillrom acquisition and growth in Medication Delivery and BioPharma Solutions. U.S. GAAP EPS was $0.14, while adjusted EPS reached $0.93. The company is navigating challenges including COVID-19 impacts, geopolitical unrest, and inflationary pressures.

Baxter International Inc. reported a 10% increase in fourth-quarter sales, reaching $3.5 billion, and a 42% increase in U.S. GAAP earnings per share to $0.47. The results include 19 days of contribution from Hillrom following its acquisition in December 2021. The company's performance reflects strong demand for its medically essential products and the impact of its ongoing transformation.

Baxter's Q3 2021 results showed a 9% increase in worldwide sales, reaching $3.2 billion. U.S. GAAP earnings per share increased by 29% to $0.89, and adjusted EPS increased by 23% to $1.02. The company has updated its full-year outlook, expecting sales growth of 7% to 8% and U.S. GAAP EPS of $2.82 to $2.86.

Baxter International Inc. reported strong second-quarter results, with a 14% increase in worldwide sales to $3.1 billion. U.S. GAAP EPS increased 23% to $0.59, and adjusted EPS increased 25% to $0.80. The company has raised its full-year sales growth expectations to approximately 8% and adjusted EPS to a range of $3.49 to $3.55.

Baxter International Inc. reported a 5% increase in first-quarter revenue, driven by Acute Therapies and BioPharma Solutions. The company's U.S. GAAP earnings per share (EPS) declined 9%, and adjusted EPS decreased by 7%. Baxter expects full-year 2021 sales growth of 8% to 9% on a reported basis.

Baxter International Inc. reported a 5% increase in fourth-quarter sales, reaching $3.2 billion. U.S. GAAP earnings per share (EPS) were $0.33, and adjusted EPS were $0.80. The company's full-year revenue was $11.7 billion, a 3% increase. Baxter provided its financial guidance for 2021, focusing on sales growth and margin expansion.

Baxter International Inc. reported a 4% increase in worldwide sales, totaling $2.97 billion. U.S. GAAP earnings per share (EPS) decreased 3% to $0.69, while adjusted EPS increased 12% to $0.83.

Baxter's second-quarter revenue totaled $2.7 billion, a decrease of 4% on a reported basis. U.S. GAAP EPS was $0.48, a decline of 20%; adjusted EPS was $0.64, a decline of 24%. The company expects full-year 2020 reported sales growth between -1% to +1% and U.S. GAAP EPS of $2.40 to $2.50.

Baxter's Q1 2020 revenue reached $2.8 billion, a 6% increase, with adjusted EPS of $0.82, up 9%. The company benefited from increased demand for essential medical products during the COVID-19 pandemic and is expanding production to meet global needs.